Genenta Science S.P.A. ADR (GNTA) Stock Price, Quote & News

Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and i...

Industry: Biotechnology

Sector: Healthcare

Phone: 39 02 26434681

Website: www.genenta.com

Address:

Via Olgettina No. 58, Milan, Italy

ForkMAN Nov. 13 at 3:53 PM

$GNTA yes, due for a push back up to that new issure price of 3.50.

0 · Reply

InvestingCat Nov. 12 at 10:39 AM

$GNTA about to get pumped more than $SLRX, don't miss out

0 · Reply

theBigDollarski Nov. 11 at 6:18 PM

$GNTA I'm in..

0 · Reply

Moneytalks4T9R Nov. 11 at 4:37 PM

$GNTA market so ugly.today no penny flipping opertunities

0 · Reply

Zackpedia Nov. 7 at 6:04 PM

$GNTA You could’ve sold when I alerted and bought back around 2 if you wanted, hit Follow and subscribe to get my alerts on time and make money

1 · Reply

Moneytalks4T9R Nov. 7 at 3:51 PM

$GNTA

0 · Reply

KillerTrader Nov. 7 at 12:09 AM

$GNTA 1,5 years ago , double Historical bottom , with 2 🥜🥜, Reverse will be strong…PR pending

1 · Reply

Moneytalks4T9R Nov. 6 at 3:49 PM

$GNTA loading zone all time low

0 · Reply

mcewing Nov. 6 at 3:46 PM

$GNTA today this hit an all time low. May 24 was $2.22

0 · Reply

Moneytalks4T9R Nov. 6 at 3:22 PM

$GNTA are we dead?

1 · Reply

Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating

Oct 26, 2025, 8:30 PM EDT - 19 days ago

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Oct 24, 2025, 4:00 AM EDT - 21 days ago

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Jul 1, 2025, 5:00 AM EDT - 4 months ago

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

May 8, 2025, 7:00 AM EDT - 6 months ago

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

May 7, 2025, 7:00 AM EDT - 6 months ago

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

Apr 15, 2025, 5:00 AM EDT - 7 months ago

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Mar 19, 2025, 9:28 AM EDT - 8 months ago

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

Jan 28, 2025, 8:01 AM EST - 10 months ago

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 9, 2025, 6:00 AM EST - 11 months ago

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

Jan 8, 2025, 3:17 PM EST - 11 months ago

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

May 6, 2024, 6:25 AM EDT - 1 year ago

Genenta Welcomes New Directors John L. Cantello, Lauren H.

Feb 8, 2024, 5:00 AM EST - 1 year ago

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Genenta to Present at Upcoming Scientific and Investor Conferences

Jul 28, 2023, 3:00 AM EDT - 2 years ago

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Jun 29, 2023, 7:00 AM EDT - 2 years ago

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Apr 3, 2023, 7:00 AM EDT - 2 years ago

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

Mar 2, 2023, 6:45 AM EST - 2 years ago

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Feb 7, 2023, 7:00 AM EST - 3 years ago

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Nov 7, 2022, 8:05 AM EST - 3 years ago

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Oct 24, 2022, 7:30 AM EDT - 3 years ago

Genenta Provides First Half 2022 Business Update and Financial Results

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Genenta to Present at Upcoming Investor Conferences

Jul 25, 2022, 6:00 AM EDT - 3 years ago

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

May 13, 2022, 7:30 AM EDT - 3 years ago

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

May 9, 2022, 7:30 AM EDT - 3 years ago

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

May 4, 2022, 4:30 PM EDT - 3 years ago

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

May 4, 2022, 7:30 AM EDT - 3 years ago

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

May 2, 2022, 4:30 PM EDT - 3 years ago

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

Apr 27, 2022, 7:30 AM EDT - 3 years ago

Genenta Announces Nomination of Mark A. Sirgo as Chair

Apr 20, 2022, 7:30 AM EDT - 3 years ago

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Mar 9, 2022, 7:46 AM EST - 4 years ago

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Feb 24, 2022, 7:30 AM EST - 4 years ago

Genenta to Participate at Upcoming Investor Conferences

Dec 17, 2021, 4:15 PM EST - 4 years ago

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Dec 14, 2021, 10:36 PM EST - 4 years ago

Genenta Announces Pricing of Upsized Initial Public Offering

ForkMAN Nov. 13 at 3:53 PM

$GNTA yes, due for a push back up to that new issure price of 3.50.

0 · Reply

InvestingCat Nov. 12 at 10:39 AM

$GNTA about to get pumped more than $SLRX, don't miss out

0 · Reply

theBigDollarski Nov. 11 at 6:18 PM

$GNTA I'm in..

0 · Reply

Moneytalks4T9R Nov. 11 at 4:37 PM

$GNTA market so ugly.today no penny flipping opertunities

0 · Reply

Zackpedia Nov. 7 at 6:04 PM

$GNTA You could’ve sold when I alerted and bought back around 2 if you wanted, hit Follow and subscribe to get my alerts on time and make money

1 · Reply

Moneytalks4T9R Nov. 7 at 3:51 PM

$GNTA

0 · Reply

KillerTrader Nov. 7 at 12:09 AM

$GNTA 1,5 years ago , double Historical bottom , with 2 🥜🥜, Reverse will be strong…PR pending

1 · Reply

Moneytalks4T9R Nov. 6 at 3:49 PM

$GNTA loading zone all time low

0 · Reply

mcewing Nov. 6 at 3:46 PM

$GNTA today this hit an all time low. May 24 was $2.22

0 · Reply

Moneytalks4T9R Nov. 6 at 3:22 PM

$GNTA are we dead?

1 · Reply

mcewing Nov. 4 at 9:46 PM

$GNTA how about some good news here? Sadly, this isn't a frequent news ticker.

0 · Reply

Zackpedia Nov. 3 at 6:27 PM

$GNTA You could’ve sold when I alerted and bought back at 2.57 if you wanted, hit Follow and subscribe to get my alerts on time and make money

0 · Reply

123MONEYGUY Nov. 1 at 3:28 PM

$GNTA what are they voting for? Dilution or what?

1 · Reply

Zackpedia Oct. 31 at 8:17 PM

$GNTA You could’ve sold when I alerted and bought back at 2.55 today if you wanted, hit Follow and subscribe to get my alerts on time and make money

0 · Reply

ForkMAN Oct. 31 at 5:20 PM

$GNTA This has a $25 price target at Wainwright?! Latest comment yesterday. Ok then...

1 · Reply

KillerTrader Oct. 31 at 2:39 PM

$GNTA INTS yesterday, dad good result phase1/2c, up 383-% , today offering at $0,80, we wait result any day from now, phase1/2 kidney cancer, we already do offering,$3,5, . We have cash for 2 years, 35 millions, low Free float.. Calm before storm

0 · Reply

mcewing Oct. 30 at 5:10 PM

$GNTA start of weeks or months long bar code around this level?

0 · Reply

Zackpedia Oct. 30 at 3:55 PM

$GNTA Selling time again at 2.98

0 · Reply

Zackpedia Oct. 30 at 12:59 PM

$GNTA You can buy back at 2.75 now if you want

0 · Reply

TheInside2028 Oct. 30 at 8:23 AM

$GNTA gap needs fill at $5.64

0 · Reply

Zackpedia Oct. 29 at 10:08 PM

$GNTA Selling time again at 2.98

0 · Reply

Zackpedia Oct. 29 at 10:07 PM

$GNTA You could’ve sold when I alerted and bought back at 2.8 if you wanted, hit Follow and subscribe to get my alerts on time and make money

0 · Reply

Market Cap	42.50M
Revenue (ttm)	0.00
Net Income (ttm)	-9.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	58,200
Avg Vol	803,996
Day's Range	N/A - N/A
Shares Out	19.15M
Stochastic %K	12%
Beta	0.55
Analysts	Strong Sell
Price Target	$21.00